SureTrader Nadex Advertisement PGUS
Home > Boards > US Listed > Biotechs >

Bio-Path Holdings Inc. (BPTH)

BPTH RSS Feed
Add BPTH Price Alert      Hide Sticky   Hide Intro
Moderator: SJSTOCKSHARK
Search This Board: 
Last Post: 3/29/2017 2:38:57 AM - Followers: 37 - Board type: Free - Posts Today: 1

Bio-path Holdings Inc.

Company Description:

Bio-Path is engaged in the business of financing and commercializing novel cancer therapeutics acquired from MD Anderson Cancer Center. Their first Antisense drug BP-1001 has completed a combination (with LDAC) safety phase  8 cohort for treatment of AML. No toxicity was seen. 5 out of 6 patients acheived at least partial remission. 50% had total remission! The company has completed the review by the FDA for this drug to begin phase II. The patient dosing has begun at trials which will occur at up to 10 sites or more, including MD Anderson, Baylor, New Jersey Hematology Oncolo
gy Associates, West Virginia University and University of Kansas.

Bio-Path Holdings is focused on antisense drugs which work at a cellular level to interrupt protein production by the diseased cell. The lead drug is BP1001 targeting the Grb-2 protein. Several years ago Gilead attempted to produce viable antisense drugs unsuccessfully because of high toxicity caused by their cationic (positively charged) liposome delivery system. Bio Path Holdings' delivery system is a small molecule neutral liposome system. Through the 8 cohort of phase 1 (treating different types of leukemia) there has been absolutely no toxicity. Testing performed by Bio Path demonstrates an uptake of the drug at a cellular level. The pErk results demonstrate not only a 50+% knockdown of the target protein but shows the pathway was shut down validating our delivery system. With the completion of the combination safety trials with LDAC and FDA approval, phase 2 has begun and is accepting patients.  This trial will occur at several sites. The purpose of phase 2 will be to test the effectiveness of the drug. The company may explore FDA accelerated status after testing is complete on 19 additional patients which is expected to occur in mid 2017. A CML combination drug safety study for BP1001 is also expected to be completed by mid 2017.
 
Bio-Path Holdings will also begin phase 1 testing of their antisense drug BP1001 on certain types of breast cancer which the date have been resistant to treatment.  Additionally, BPTH is initiating development of a second drug BP1002 targeting Bcl-2 for Follicular Lymphoma. An IND for BP1002 is projected for early 2017.

The company has entered into a sponsored research agreement with the University of Texas Southwestern Medical Center to evaluate BPTH's pipeline for efficacy in down-regulating the immune response using systemic lupus erythematosus (SLE) as a model. Bio-Path has entered into a sponsored research agreement with Thomas Jefferson University to investigate DNAbilize™ antisense DNA technology for the development of a brain cancer immunotherapy that works by activating the patient’s own immune system to fight their cancer. Also, BPTH has entered into a sponsored research agreement with MD Anderson to evaluate the ability of its pipeline to modulate pancreatic cancer.


http://www.biopathholdings.com


While antisense drugs fell out of favor following Gilead's failed efforts there is now renewed interest.  Ionis established partnerships with Biogen Idec and GlaxoSmithKline for their antisense technology. If Bio-Path holdings proves the validity of their delivery system, I would expect similar partnerships.

This link to the company website describes their novel delivery technology:


http://biopathholdings.com/technology/


The company was founded on the technology from M.D. Anderson Cancer Center at the University of Texas in Houston. M.D. Anderson was the largest shareholder. After raising an additional 10 million dollars the company has $11+ million in cash. These funds should allow the company to start phase II testing of their antisense drug BP1001 on leukemia and begin phase I testing for breast cancer. The company has an "at the market" credit facility in place with Cantor Fitzgerald to raise another $25 million.

 
Bio-Path Holdings do not manufacture their drug but uses contractors. Once the efficacy of BP1001 is established, I would anticipate a manufacturing partnership will occur. The CEO says the company has now ramped up their structure as they are a phase 2 developmental company.
 
BPTH is traded on the NASDAQ.

Here is the link to the peer paper prepared by their experts:


http://www.abstractsonline.com/pp8/#!/4292/presentation/2610

http://www.biopathholdings.com/pdf/PeerExpertOpinion20150107.pdf

Analyst target price: Maxim $2, Rodman & Renshaw $5

Zack's upgraded rating now equals 3 or hold.
                        
 
 
 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
BPTH
Current Price
Volume:
Bid Ask Day's Range
SureTrader
PostSubject
#2542   SJ, your concerns are duly noted. I Snug9 03/29/17 02:38:57 AM
#2541   Amazing isn't it? I think Peter goes to the wingshooterr 03/28/17 02:39:12 PM
#2540   Here is the SEC link: SJSTOCKSHARK 03/28/17 11:58:26 AM
#2539   Did anyone else see new SEC filings showing SJSTOCKSHARK 03/27/17 11:00:37 PM
#2538   That would make sense. I seem to Pat Torney 03/25/17 01:48:18 PM
#2537   Pat, I suspect they are patent pending but SJSTOCKSHARK 03/24/17 05:11:39 PM
#2535   I believe others have sent emails to investor Pat Torney 03/24/17 04:53:11 PM
#2534   Pat, This is pretty serious is Peter is stating cautious optimist 03/24/17 04:02:27 PM
#2533   My comments on PN's claims of patent protection. Pat Torney 03/24/17 12:54:19 PM
#2532   Quick question for this forum. Does the bod too simple 03/24/17 09:45:14 AM
#2531   Wings, You are shooting straight on both PN's SJSTOCKSHARK 03/23/17 09:39:53 PM
#2530   PN pumps a lot of air out of wingshooterr 03/22/17 10:56:15 PM
#2529   On the Oppenheimer conference: 1. The presentation was clear, Gpheart2016 03/22/17 01:42:12 PM
#2528   Oppenheimer presentation: SJSTOCKSHARK 03/22/17 12:35:04 PM
#2527   They are going to have to raise more iloveu2 03/21/17 03:16:11 PM
#2526   GP, The stock price makes no sense. Are SJSTOCKSHARK 03/19/17 09:49:00 PM
#2525   I would be amazed if he receives a BPTH2008 03/19/17 06:58:59 PM
#2524   Not yet, he just sent it on Friday afternoon. Brettj 03/19/17 10:22:54 AM
#2523   Brettj, Did he receive a reply? SJSTOCKSHARK 03/18/17 11:17:28 PM
#2522   My dad convinced me to through a few Brettj 03/18/17 12:28:37 PM
#2521   SJ, you might be right that BP-1002 does Gpheart2016 03/16/17 10:33:00 AM
#2520   SJS, thanks for your level headed posts. I too simple 03/15/17 09:08:24 PM
#2519   PN's Wasatch front background is a stock killer tyroneweaver 03/15/17 07:46:59 PM
#2518   GP, BP-1002 will not matter as the company SJSTOCKSHARK 03/15/17 07:36:04 PM
#2517   Make bpth pay and sell, sell, sell, this iloveu2 03/15/17 03:33:38 PM
#2516   Brett, you are right ! I admit I too simple 03/15/17 02:11:49 PM
#2515   Peter speaks and the stock price plummets. To Brettj 03/15/17 01:54:13 PM
#2514   This is going to get ugly! iloveu2 03/15/17 01:11:30 PM
#2513   Once again, it looks like we cannot break Gpheart2016 03/15/17 12:39:05 PM
#2512   Earnings conference results: SJSTOCKSHARK 03/15/17 12:19:25 PM
#2509   Rives Journal SJSTOCKSHARK 03/14/17 03:24:30 PM
#2508   Wouldn't they do that at the quarterly meeting dmoffat 03/14/17 02:45:37 PM
#2507   News What does a corporate overview mean? SJSTOCKSHARK 03/14/17 10:26:08 AM
#2506   Agree, the public is always the last to too simple 03/13/17 04:12:04 PM
#2505   Maybe the quarterly report isn't final yet? I SJSTOCKSHARK 03/13/17 04:09:47 PM
#2504   How is it there always seems to be Pat Torney 03/13/17 03:11:10 PM
#2503   Dmoffat, I think we can hope that there Gpheart2016 03/13/17 11:48:04 AM
#2502   Does anybody have a previous example of a dmoffat 03/13/17 11:05:12 AM
#2501   BPTH now has red! on Fidelity active trader SJSTOCKSHARK 03/10/17 03:32:03 PM
#2500   Here is the abstract: SJSTOCKSHARK 03/10/17 11:46:27 AM
#2499   At least some news: SJSTOCKSHARK 03/10/17 11:36:10 AM
#2498   But the sites have increased from three to Gpheart2016 03/10/17 11:15:03 AM
#2497   GP, remember PN predicted 10 sites by the SJSTOCKSHARK 03/09/17 10:22:09 AM
#2496   Ty, Yes we can go back to the SJSTOCKSHARK 03/09/17 10:16:53 AM
#2495   In the midst of bad news (possible delisting Gpheart2016 03/09/17 09:58:13 AM
#2494   Can we go back to a bulletin board stock? tyroneweaver 03/09/17 01:10:11 AM
#2493   With the recent stock price performance you would SJSTOCKSHARK 03/08/17 08:42:49 PM
#2492   I'm sure Peedee has LLC protection tyroneweaver 03/08/17 07:22:34 PM
#2491   I guess you can tell I am getting too simple 03/08/17 05:36:00 PM
#2490   Well isn't that freaking wonderful! Someone needs to dmoffat 03/08/17 04:46:58 PM
PostSubject